BillionToOne Collaborates with Epic to Integrate Testing Services
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3d ago
0mins
BillionToOne announced a collaboration with Epic, a comprehensive electronic health record. The agreement will integrate BillionToOne's prenatal and oncology testing portfolio with Epic's Aura diagnostics suite. Through the integration, clinicians will be able to order BillionToOne's UNITY Complete prenatal test as well as Northstar Select and Northstar Response liquid biopsy tests directly within Epic. Discrete test results then flow back into the electronic health record, where they can power downstream clinical decision support.
Analyst Views on BLLN
Wall Street analysts forecast BLLN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLLN is 137.83 USD with a low forecast of 110.00 USD and a high forecast of 160.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 94.720
Low
110.00
Averages
137.83
High
160.00
Current: 94.720
Low
110.00
Averages
137.83
High
160.00
No data
About BLLN
BillionToOne, Inc. is a precision diagnostics company that quantifies biology to create molecular diagnostics. The Company's proprietary molecular counting platform is designed to detect and measure deoxyribonucleic acid (DNA) molecules at a single-count level to help improve disease detection. It applies the proprietary technology to non-invasive prenatal screening (Prenatal) and liquid biopsy (Oncology). Its Quantitative Counting Templates (QCTs), power its ability to detect and measure tiny and sparse disease-related DNA fragments, or molecules, at the single base-pair level. These include pregnancy-related DNA that code for recessively inherited conditions such as sickle cell disease and cystic fibrosis and ctDNA in the case of cancer. Its prenatal products include UNITY Complete, UNITY Fetal Risk Screen, UNITY Aneuploidy Screen, UNITY Fetal RhD NIPT, UNITY Fetal Antigen NIPT, and UNITY Fetal Antigen CTA NIPT. Its oncology products include Northstar and Northstar Select.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
